NuGene International, Inc. Reports Expanded Distribution Channels and Increased Growth in Q4 2014

IRVINE, Calif., Feb. 9, 2015 /PRNewswire/ -- NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the maker of age-defying  aesthetic products for skin and hair rejuvenation developed from adult adipose stem cells and other biologically active ingredients, announced today that its 2014 launch into physician, aesthetician and medical spa channels achieved significant continued growth through the year, with a fourth quarter product sales volume that nearly matched the product revenue of the prior three quarters combined.

"We are elated at the positive feedback that we have received from the growing number of doctors, aestheticians and other skin and hair care professionals who have used and recommended our products over the past year," stated Ali Kharazmi CEO of NuGene. "We are rapidly transitioning from being a provider of proprietary cosmeceuticals to our affiliated surgery centers to a business that is intensely focused on broad based cosmeceutical distribution throughout the skin and hair care industry," he explained. "Beginning in the first quarter of 2014," Mr. Kharazmi noted, "we initiated a beta rollout of our cosmeceutical products to physician, aesthetician and medical spa locations. Our focus," he added, "has been to spur growth by working closely with each distributor to affirm the benefits of our total product line and by providing dedicated and attentive customer service."

During the fourth quarter of 2014, NuGene expanded its total distribution base by 200% in comparison to the third quarter of 2014. "Our cosmeceutical product revenues for the last quarter," observed Mr. Kharazmi, "have increased significantly over the first nine months of 2014.  We will continue to expand distribution and revenue growth throughout 2015 by developing distribution networks both domestically as well as internationally to increase market presence and awareness."

About NuGene International, Inc.

NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media.  The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments".  The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report.  NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue.  NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations.  The company has two patents pending covering 15 unique applications and inventions.  NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations
(949)481-9739

Logo - http://photos.prnewswire.com/prnh/20150209/174216LOGO

SOURCE NuGene International, Inc.